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Introduction: The progression and clinical course of head and neck squamous cell
carcinoma (HNSCC) relies on complex interactions between cancer and stromal cells in
the tumor microenvironment (TME). Among the most abundant of these stromal cells are
cancer-associated ﬁbroblasts (CAFs). While their contribution to tumor progression is
widely acknowledged, and various CAF-targeted treatments are under development, the
relationship between CAF density and the clinicopathologic course of HNSCC has not
been clearly deﬁned. Here we examine the published evidence investigating the
relationship of cancer-associated ﬁbroblasts to local recurrence and indicators of
prognostic signiﬁcance in HNSCC.
Methods: We conducted a meta-analysis of existing publications that compare the
relationship between CAF density, local recurrence, and clinically signiﬁcant pathologic
criteria of disease development (T stage, nodal positivity, clinical stage, vascular invasion,
perineural invasion, Ki67 expression, and differentiation). Thirteen studies met the
selection criteria, providing a total study population of 926 patients. Forest plots and
risk ratios were generated to illustrate overall relationships.
Results: Higher CAF density within the tumor microenvironment is associated with
advanced T stage, nodal inﬁltration, clinical stage, vascular invasion, perineural invasion,
Ki67 expression, and differentiation (p <0.05). High CAF density is also associated with
increased rates of local recurrence (p <0.001).
Conclusions: Across multiple studies, increased CAF density is correlated with
histopathological criteria of poor prognosis in HNSCC. These ﬁndings highlight that CAFs
may play a pivotal role in HNSCC development and progression. Staining for CAFs may
represent a valuable addition to current pathologic analysis and help to guide prognosis and
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treatment. Understanding the mechanisms by which CAFs reciprocally interact with cancer
cells will be crucial for optimization of TME-focused treatment of HNSCC.
Keywords: cancer-associated ﬁbroblasts, CAF, tumor microenvironment, myoﬁbroblast, alpha-smooth muscle
actin, prognosis, head and neck squamous cell carcinoma

(28, 29). Articles found from the search were selected for further
analysis according to the following criteria: (1) English language; (2)
human subjects; (3) squamous cell carcinoma of the head and neck;
(4) measurement of CAFs using either alpha-smooth muscle actin
(a-SMA) or Fibroblast Activation Protein (FAP) via
immunohistochemistry; (5) available data on one or more of the
following clinical and pathologic characteristics: T stage, N stage,
clinical stage, vascular invasion, perineural invasion, Ki67,
differentiation, and recurrence. After identiﬁcation, screening,
and determination of eligibility, 13 studies were included in the
meta-analysis (Figure 1) (22, 24, 25, 28–38). Based on the methods
of the selected studies, as well as to facilitate analysis with
dichotomous variables, the pathologic markers were grouped in
the following manner: advanced T stage included T3 or T4 lesions;
nodal positivity included all tumors staged N1–3; clinical stages of
III and IV were classiﬁed as advanced; poor differentiation was
applied to only those samples truly graded as poor; vascular
invasion was deemed to be positive or not positive; Ki67 staining
was graded as high or low based on a cutoff percentage of positive
staining (range: 26–32.4%); perineural invasion was noted to be
present or not present; recurrence was either present or not present.
No standard scoring system exists to assess the density of CAFs with
particular samples. However, all studies included in this analysis
used semi-quantitative methods, based on intensity and/or extent of
positive staining, to assess and classify CAF density. The methods
utilized by each study are noted in Table 1. In this analysis, samples
with intermediate and high density of CAFs, as determined by the
individual study, were grouped together into a high CAF group.
This group was compared to a low CAF group, with weak or
negative staining in the tumor samples. Correction for multiple
testing was not performed. Forest Plots were generated using the
Review Manager 5.3 Software (40). Plot speciﬁcations were
dichotomous for data type, ﬁxed effect for analysis method, and
risk ratio for effect measure.

INTRODUCTION
Over the last thirty years, multiple lines of evidence have illuminated
the importance of the tumor microenvironment (TME) to the
development of solid malignancies. Tumor cells and the
components of the TME bidirectionally communicate to support
neoplastic growth and expansion (1–4). Elements of the TME
evolve over time and are reprogrammed to cater for the needs of
a growing tumor (5, 6). These observations have changed our
understanding of cancer progression and behavior. Once thought
to be an isolated group of diseased cells, many malignant tumors,
including Head and Neck Squamous Cell Carcinomas (HNSCC),
are now regarded as a sophisticated and dynamic tissue consisting of
multiple cell types (7–11). Cancer-associated ﬁbroblasts (CAFs) are
among the most abundant cells within this tissue.
During tumorigenesis, CAFs develop alongside epithelial cancer
cells and adopt a distinct, activated, phenotype (12). As ﬁbroblasts
become activated, they express alpha-smooth muscle actin (a-SMA),
signifying a myoﬁbroblast phenotype and contractile function,
similar to ﬁbroblasts participating in wound healing (13, 14). In
solid tumors, historically described as “wounds that do not heal”,
these ﬁbroblasts remain persistently activated as CAFs (15). CAFs
modulate the TME via the secretion of autocrine and paracrine
cytokines, as well as extracellular matrix components that provide
scaffolds to support the growing tumor cell nests. Many of the classic
“hallmarks of malignancy”, as well as emerging hallmarks such as
immune evasion and metabolic compartmentalization, are
inﬂuenced by the presence and functional states of CAFs (6, 16–19).
Similar to other solid cancers, the presence of CAFs in the
tumor stroma of HNSCC has been associated with poor survival
(20–22). It has been suggested that a-SMA staining is a better
predictor for disease mortality than traditional TNM staging
(23). However, other studies have not found an association with
survival (24, 25).
In this meta-analysis, we sought to synthesize the existing
literature to better deﬁne the relationship of CAF density on
indicators of HNSCC aggressiveness and prognosis as deﬁned by
tumor stage and speciﬁc histologic ﬁndings on tumor biopsy (26,
27). By deﬁning the signiﬁcance of CAF density within a
prognostic framework, utilization of CAFs in clinical medicine
can be optimized.

RESULTS
Characteristics of the 13 studies included in this analysis are
shown in Table 1. These studies represent a population of 926
patients with surgically resected samples. Twelve studies (897
patients) used samples from oral squamous cell carcinoma, with
one of the twelve limiting their analysis to advanced (T3 or T4)
oral samples (31). The remaining study evaluated 29 patients
with various Head and Neck SCC primary sites including
sinonasal, oral, and laryngeal (34). Six studies reported clinical
stage according to guidelines from the Union for International
Cancer Control and American Joint Committee on Cancer, while
three studies reported TNM stage without specifying which

MATERIAL AND METHODS
A PubMed search using the following keywords was performed:
(“Cancer Associated Fibroblasts” OR “CAFs”) AND (“squamous
cell carcinoma”). Preferred Reporting Items Systematic Reviews
and Meta-Analyses (PRIMSA) recommendations were followed
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FIGURE 1 | Flowchart of systematic review.

TABLE 1 | Characteristics of studies evaluating CAF density and clinicopathologic markers in HNSCC.
Author

Year

Akrish et al.
(25)
Ding et al.
(22)
Fujii et al.
(24)
Kellermann
et al. (28)
Kellermann
et al. (30)
Liang et al.
(31)
Lin et al.
(32)
Luksic et al.
(33)
RamosVega et al.
(34)
Sun et al.
(35)
Takahashi
et al. (36)
Wang et al.
(37)
Zhang et al.
(38)

Site of
Cancer

Number
of
Patients

Age of Patients
(years)

2017 Oral SCC

65

a-SMA

No neoadjuvant therapy

2014 Oral SCC

50

a-SMA

No neoadjuvant therapy

2012 Oral SCC

108

28 patients <65,
37 patients >65
Mean: 53.5 (26–
74)
Mean: 66.4 (23–
93)

a-SMA

No neoadjuvant therapy

2007 Oral SCC

83

a-SMA

No neoadjuvant therapy

2008 Oral SCC

38

a-SMA

No neoadjuvant therapy

2018 Advanced
Oral SCC

26

42 patients ≤58,
41 patients >58
Mean: 61.1 (43–
89)
12 patients <50,
14 patients ≥50

a-SMA

2017 Oral SCC

86

a-SMA

Before chemotherapy
sample used for metaanalysis
No neoadjuvant therapy

2015 Oral SCC

152

a-SMA

No neoadjuvant therapy

2020 Head and
Neck SCC

29

a-SMA

No neoadjuvant therapy

• As described by Fujii et al.
• Based on density and concentration of CAFs

2019 Oral SCC

47

a-SMA

No neoadjuvant therapy

2016 Oral SCC

73

a-SMA

No neoadjuvant therapy

2019 Oral SCC

121

a-SMA

No neoadjuvant therapy

2016 Oral SCC

48

a-SMA

No neoadjuvant therapy

• Method described in Cheng et al. (39)
• Based on CAF density
• According to previously described techniques
(Kellermann et al., Fujii et al.)
• Based on CAF density
• Method described by Fujii et al.
• Based on density and concentration of CAFs
• Based on extent of positive staining (high ≥25%)

26 patients ≤50,
60 patients >50
26 patients ≤50,
60 patients >50
Mean: 57 (34–
81)
17
30
17
30

patients <60,
patients ≥60
patients <60,
patients ≥60

Mean: 60.2 (34–
88)
Not reported

CAF
marker
used

Prior Therapy Received

Determination of CAF burden in samples

• Method proposed by Bello et al.
• Based on CAF density
• Based on CAF density
• Modiﬁed classiﬁcation system as described by
Kellermann
• Based on density and concentration of CAFs
• Rated as negative, scanty, or abundant as determined
by three independent pathologists
• Rated as negative, scanty, or abundant as determined
by three independent pathologists
• Based on staining intensity multiplied by percentage of
positive staining, Median cutoff between high and low
• Based on staining intensity multiplied by percentage of
positive cells (each graded 0–3)
• Based on Proportion of positive-staining area

CAFs, Cancer-Associated Fibroblasts; SCC, Squamous Cell Carcinoma; a-SMA, alpha-Smooth Muscle Actin.
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studies and eleven of the studies demonstrated a positive
relationship of CAF density and nodal invasion. The
cumulative risk ratio of these studies was 1.82 (95%CI = 1.50–
2.22, p <0.001). The average rate of nodal positivity in high CAF
samples was 49.3%, compared to 29.0% of low CAF tumors.

staging guidelines were utilized. All studies utilized samples from
treatment-naïve patients. All thirteen studies assessed a-SMA
expression to determine CAF presence.

Increased CAF Density Is Associated With
Advanced T Stage

Increased CAF Density Is Associated With
Advanced Clinical Staging

Higher density of CAFs in the tumor microenvironment is
associated with stages T3 and T4 HNSCC (Figure 2). Seven
studies examined the relationship of CAF density and T stage; all
seven showed higher density of CAFs was related to increased
risk of high T stage tumors. The combined risk ratio of the
studies was 1.82 (95%CI = 1.43–2.32). This relationship was
statistically signiﬁcant (p <0.001). The rate of advanced T stage in
samples with high CAF density was 42.2%, compared to 28.7% of
those with low CAF density.

High density of CAFs within the microenvironment correlated with
advanced clinical staging of HNSCC tumors (TNM classiﬁcation)
(Figure 4). Nine studies examined this relationship and all nine
demonstrated higher TNM classiﬁcation in those tumors with high
CAF density. The cumulative risk ratio was 1.82 (95%CI = 1.54–
2.16, p <0.001). The average rate of advanced clinical stage was
67.8% in tumors with high CAF density. In tumors with low CAF
density, the average rate was 41.1%.

Increased CAF Density Is Associated With
Lymph Node Metastasis

Increased CAF Density Is Associated With
Higher Rates of Vascular Invasion

High density of CAFs in the primary tumor TME is associated
with increased rates of tumor cell dissemination to regional
lymph nodes (Figure 3). The relationship of CAFs and nodal
inﬁltration was examined in twelve of the thirteen selected

Similarly, CAF density is associated with increased rates of vascular
invasion (Figure 5). Two studies examined this relationship and
both showed statistically signiﬁcant risk ratios. The resulting risk
ratio of these studies was 3.28 (95%CI = 1.52–7.09, p = 0.002). In

FIGURE 2 | Increased density of CAFs in HNSCC is associated with advanced T stage.

FIGURE 3 | Increased CAF density is associated with lymph node metastasis.
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FIGURE 4 | Increased CAF density is associated with high clinical stage.

FIGURE 5 | Increased CAF density is associated with high rates of vascular invasion.

samples that exhibited higher density of CAFs, the average rate of
vascular invasion was 35.1% whereas only 9.0% of samples with low
CAFs density showed vascular invasion.

Increased CAF Density Is Associated With
Higher Levels of Ki67 Expression
Higher density of CAFs in the TME is correlated with higher levels
of Ki67 expression, a measure of cell proliferation (Figure 7).
Three studies assessed Ki67 levels within the tumor and all three
reported a positive relationship between CAF content and Ki67
staining. Some 56.2% of the total number of samples with high
CAF density showed high levels of Ki67, compared to 40.0% of the
samples with low CAF density. The combined risk ratio of these
studies was 1.51 (95%CI = 1.13–2.03, p = 0.006).

Increased CAF Density Is Associated With
Higher Rates of Perineural Invasion
Greater density of CAFs in the TME is associated with higher
rates of perineural invasion (PNI) in HNSCC (Figure 6).
Perineural invasion, wherein tumor cells are found to inﬁltrate
the nerve sheath, provides a distinct form of metastatic spread in
HNSCC. Two studies examined this relationship, and both
showed a positive relationship between CAF density and PNI.
40.0% of samples with high CAF density demonstrated PNI,
while 23.9% of samples with low CAF density had PNI upon
pathologic examination. These studies had a cumulative risk
ratio of 1.66 (95%CI = 1.02–2.69) which was statistically
signiﬁcant (p = 0.04).

Increased CAF Density Is Associated With
Poor Differentiation
High CAF density within the TME is further associated with
poor differentiation of HNSCC (Figure 8). Ten of the thirteen
selected studies determined the relationship between these
characteristics; nine of them demonstrated a positive

FIGURE 6 | Increased CAF density is associated with high rates of perineural invasion.
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FIGURE 7 | Increased CAF density is associated with increased cellular proliferation, as determined by Ki67 staining.

FIGURE 8 | Increased CAF density is associated with poor differentiation of tumor.

relationship. The average rate of poor differentiation in high CAF
density tumors was 19.3%, while low CAF density tumors
displayed poor differentiation 13.6% of the time. The resulting
risk ratio was 1.90 (95%CI = 1.35–2.69, p <0.001).

DISCUSSION
HNSCC, for which mortality remains high despite recent advances
in malignancy treatment, demonstrates a remarkable quantity of
CAFs, up to 80% of tumor volume in later stage tumors (41, 42).
The existing literature has suggested that CAFs negatively affect
prognostic characteristics in HNSCC but has not produced a
uniform conclusion, with some studies failing to show an
association and others claiming a strong positive association (20–
25). Two recent meta-analyses have shown that high CAF density is
associated with worse overall survival in oral SCC (20, 43). This
paper sought to clarify the relationship between CAFs, recurrence,
and clinicopathologic markers of signiﬁcance in HNSCC, including
13 independent studies for a study population of over 900 patients.

Increased CAF Density Is Associated With
Increased Rates of Local Recurrence
High CAF density within the TME is associated with increased
rates of local recurrence of HNSCC (Figure 9). Six studies
examined this relationship with ﬁve studies reporting higher
recurrence rates in high CAF density tumors. The cumulative
risk ratio was 1.84 (95%CI = 1.35–2.53, P <0.001). The average
rate of local recurrence was 31.8% in high CAF density samples,
compared to 22.7% in low CAF density samples.

FIGURE 9 | Increased CAF density is associated with local recurrence.
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To our knowledge, this is the ﬁrst quantitative meta-analysis to
examine these relationships. Taken together, the present study
shows that, in HNSCC, CAFs are associated with poor prognostic
characteristics and increased rates of local recurrence.
This analysis demonstrated that high density of CAFs is associated
with higher clinical stage, including T stage and TNM stage (Figures
2 and 4). These characteristics were reported by most of the published
studies and demonstrated strongly positive risk ratios. Although
some publications did not demonstrate a statistically signiﬁcant
relationship, the relationship with T stage and TNM stage was
uniform among the studies. This may be attributable to the
aforementioned CAF burden in late stage HNSCC, wherein CAFs
accumulate and contribute to high proportions of tumor volume.
The presence of high density of CAFs is associated with common
modes of tumor spread and metastasis, including perineural
invasion, vascular invasion, and lymph node metastasis (Figures
3, 5 and 6). These insidious ﬁndings are indicative of a propensity
for metastasis and often suggest the need for more aggressive
treatment. The relationship between lymph node metastasis and
CAF density was not uniform in the literature, with one study
showing an inverse, although non-signiﬁcant, relationship (32).
This meta-analysis revealed a strong positive association, with a
cumulative risk ratio of 1.82. Vascular invasion and PNI were the
least reported ﬁnding among the literature, with only two studies
remarking on their association with CAFs. Both studies that
investigated vascular invasion showed a statistically signiﬁcant
effect of CAFs on vascular involvement. This was reﬂected in the
analysis, with vascular invasion demonstrating the highest risk ratio
of all prognostic indicators (3.28), exceeding the 95% conﬁdence
interval for all other pathologic variables. Both studies that assessed
the relationship with PNI demonstrated increased rates in tumors
with high CAF density, however neither demonstrated independent
statistical signiﬁcance between high and low CAF groups. In total,
this study suggests that CAFs play a mechanistic role in invasion
and correlates with the presence of various forms of cancer spread.
Similarly, high density of CAFs in tumor samples was
signiﬁcantly associated with aggressive histologic features,
including poor differentiation and high Ki67 expression
(Figures 7 and 8). Most studies reported a positive association
between CAFs and histologic ﬁndings of poor prognosis;
however, few studies met statistical signiﬁcance individually.
The relationship between differentiation and CAF density was
particularly uncertain in this literature, with only one published
study showing a signiﬁcant relationship (25). However, when
summed together, the cumulative literature demonstrated a
statistically signiﬁcant association. The strength of the risk
ratios for both poor differentiation and high Ki67 expression
were high (1.45 and 1.51, respectively), illustrating a clear
association of CAFs with tumor aggressiveness and behavior.
This study showed a signiﬁcant association of high CAF
density with rates of local recurrence (Figure 9). Within the
literature, this relationship had not been clearly demonstrated,
with only two of six studies demonstrating a statistically
signiﬁcant association (32, 37). Our analysis showed a strongly
positive risk ratio (1.84), suggesting that CAF density is a
clinically meaningful indicator of disease course and outcome.

Frontiers in Oncology | www.frontiersin.org

These ﬁndings strongly support the hypothesis that the
density of CAFs in HNSCC is associated with multiple poor
prognostic factors. Similarly, we demonstrate that high density of
CAFs is associated with increased rates of local recurrence. This
evidence provides a strong rationale to further investigate the
functional relationship of CAFs with carcinoma cells in the
tumor microenvironment. Furthermore, this work suggests
that staining for CAFs is an indicator of clinical outcomes and
may be a valuable addition to existing prognostic strategies.
Immunohistochemical staining for a-SMA was the most
commonly utilized method for detecting CAFs in the
microenvironment. This allowed for a more homogenous study
population and facilitated the comparison between different
studies. Other markers for assessing the presence of CAFs have
also been suggested in the literature. Higashino et al. performed
both FAP and a-SMA staining on esophageal SCC samples and
found different staining patterns between the two populations
(44). Differences in staining between these markers, and other
proposed CAF identiﬁers, may represent differing origins or
functional subtypes of CAFs. The ﬁndings in this meta-analysis
may be most applicable for a-SMA+ CAF subtypes. Further
studies to investigate the differences between these subtypes
are needed.
Knowledge of CAFs allows for better understanding of
tumorigenesis and increases the feasibility of CAF-directed
treatment. Bidirectional interaction between CAFs and tumor
cells has been demonstrated in multiple studies and may
contribute to the increased tumor aggression and dissemination
shown in this meta-analysis.
Although the origin of CAFs in the TME have yet to be clearly
deﬁned, the current consensus is that local tissue ﬁbroblasts are
activated to become CAFs, under the inﬂuence of tumor-derived
paracrine factors and cytokines (28, 45, 46). Once activated, CAFs
give rise to physical and chemical changes within the
microenvironment that facilitate enhanced growth and
progression as shown in this data. Through secretion of cytokines
like transforming growth factor-beta (TGF-b), CAFs induce a
desmoplastic response in the surrounding environment,
synthesizing collagen which stiffens the tissue and alters
homeostasis (47). The mechanical stress of desmoplasia collapses
nearby blood vessels to promote hypoxia, resulting in more
aggressive cancer phenotypes. Recurrent malignancy after
treatment with radiation exempliﬁes this phenotype. Orchestrated
by CAFs, these recurrences are often exquisitely desmoplastic with
extensive collagen cross linking and loss of microvascular structure
(48, 49). This modiﬁed environment is hypothesized to provide a
physical barrier to immune surveillance, enabling unabated tumor
growth (50).
Metabolic coupling between CAFs and HNSCC cells further
drives tumor development. CAFs demonstrate a “reverse
Warburg” effect wherein oxidative stress to tumor cells induces
glycolytic behavior and autophagy in nearby CAFs. Catabolites
produced in this glycolytic process are then shuttled to tumor
cells via monocarboxylate transporters (MCTs), allowing for
mitochondria-rich tumor cells with high rates of Oxidative
Phosphorylation (42, 51). These changes serve to “feed”
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anabolic tumors cells (52, 53). The ﬁndings in this meta-analysis,
linking higher CAF density with larger, and more aggressive,
primary tumors may reﬂect this symbiosis.
As noted above, CAFs possess the capacity to directly and
indirectly alter the host immune response. CAFs in HNSCC can
modulate the function and suppress proliferation of T cells,
contributing to the immunosuppressive environment in HNSCC
lesions (54, 55). Cytokines secreted by CAFs reportedly promote the
attraction of tumor-associated macrophages and skew their
differentiation state towards the M2 subtype, which is linked to
poor prognosis and outcomes in HNSCC (36, 56, 57). The presence
of CAFs may allow tumors to evade immune surveillance and
weaken immune response, providing a permissive environment for
tumor growth and proliferation.
This meta-analysis demonstrated a strong association
between CAF density and tumor invasion. The impact of CAFs
on invasion is multifaceted, involving changes to both the TME
and cancer cells themselves. It is well documented that CAFs
serve to remodel the extracellular matrix and promote “tracks”
for invading tumor cells (58). Tumor migration and invasion is
supported by CAFs through the secretion of matrix-dissolving
proteases including matrix metalloproteins (MMPs) and growth
factors including TGF-b (59, 60). Local invasion facilitates
dissemination to lymph nodes and neurons, as demonstrated
by the increased rates of lymph node positivity and PNI shown in
this meta-analysis. Secretion of TGF-b by CAFs may additionally
support migration and invasion of tumor cells through robust
effects on the epithelial-to-mesenchymal transition (EMT) of
HNSCC and enhanced metastatic potential (61).
Prognostication and clinical stratiﬁcation remain a difﬁcult
task in HNSCC. Recent staging modiﬁcations by the AJCC have
expanded to incorporate extra-nodal extension and depth of
invasion into their algorithm (62). However, patients with
identical staging may have disparate outcomes. Histopathology
may provide valuable data to be incorporated into clinical
decision making. Marsh et al. found a-SMA to be the most
signiﬁcant prognostic indicator of all clinical, pathologic, and
molecular features (23). Our ﬁndings, and recent studies
correlating high CAF density with overall survival, support

further consideration of CAF utilization within existing
prognostic algorithms (20, 43).
The prognostic qualities of CAFs may not be applicable to
precancerous lesions. Vered et al. showed a “burst” of CAFs that
coincided with the appearance of tongue carcinoma, but not in
hyperplastic or dysplastic lesions (63). A study by EtemadMoghadam et al. demonstrated no a-SMA staining in either
normal oral epithelium or oral dysplasia, but all samples of oral
carcinoma contained CAFs, to varying degrees (64). This differs
from the paradigm seen in other cancer types including colon,
breast, and cervical (65–67), wherein a-SMA positive
myoﬁbroblasts are present in non-invasive lesions and are
thought to promote the progression to carcinoma. Similarly,
HPV-positive HNSCC has a unique pathogenesis with different
CAF stimulation and activation patterns than those found in HPVnegative disease (68, 69). Further investigation into HPV-associated
CAF quantities and function will help to clarify this interaction and
guide future treatment.
Tumors with invasive phenotypes or poor differentiation
often have a high stromal burden, consisting of large CAF
populations. It is important to determine whether differences
in prognosis associated with CAF density could be attributable to
intrinsic tumor characteristics. To this end, Sun et al. cultured
identical SCC lines with either normal ﬁbroblasts or CAFs,
demonstrating increased invasion and migration in cell lines
co-cultured with CAFs compared to normal ﬁbroblasts (35).
Similar ﬁndings have been seen in breast cancer experiments
(70). These in vitro studies offer some insight into the
deterministic impact of CAF; however, continued research is
necessary to understand how speciﬁc CAF and tumor cell
interactions result in the prognostic effects shown here.
As the speciﬁc impact of CAFs in HNSCC has been better
elucidated, CAF-targeted treatment have emerged. For example,
inhibitors of Fibroblast Activation Protein (FAP), have shown
promising preclinical results in reducing the progression of
tumors and promoting anti-tumor immune response (71–73).
Similarly, CAF-derived cytokines, like HGF and TGF-b, have
been targeted to inhibit tumor aggressiveness and slow resistance
to traditional chemotherapy (74, 75). A better understanding of

FIGURE 10 | Summary.
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between CAF density and prognostic indicators; to determine
causality, further investigation would need to be undertaken.
Finally, and as discussed above, the heterogeneity of CAF
populations, even within a single tumor, should not be
underestimated. Distinct CAF subtypes have been suggested in
HNSCC and each subpopulation may hold distinct prognostic
signiﬁcance (76). While this study utilized a broad and
encompassing categorization of CAFs, certain subpopulations
may have stronger clinical implications.

the functional relationship of CAFs and malignant cells is likely
to guide identiﬁcation of additional therapeutic targets
in HNSCC.
Further complicating our understanding, CAFs show
remarkable heterogeneity and plasticity. Despite underlying
commonalities, CAFs within a single tumor may arise via
different pathways, have different phenotypes, and exhibit
functionally different effects on the tumor cells and
environment (75–77). This is exempliﬁed by the different
expression patterns seen in different methods of CAF
identiﬁcation (44). As recent research has shown, CAF
function can be altered by environmental factors (19). Many
believe that CAFs, like tumor-associated macrophages, may have
either pro-tumoral or anti-tumoral effects depending on subtype
or activation (78). This may in part explain why complete aSMA depletion in mouse models resulted in aggressive
pancreatic tumors and reduced survival (79).
Single cell technologies, such as RNA sequencing (scRNA-seq),
have recently provided the ability to assess the transcriptional and
phenotypical heterogeneity of CAFs. These approaches offer the
ability to unmask speciﬁc cellular subtypes via their transcriptome,
providing greater resolution than a-SMA staining. ScRNA-seq
research in breast and colon cancer have shown clear delineations
between CAF sub-populations (80, 81). Projects that seek to deﬁne
these subtypes in HNSCC and their prognostic and mechanistic
effects are necessary, both for understanding of tumorigenesis and
optimization of therapy.

Conclusion
CAFs play pivotal roles within the microenvironment of various
solid malignancies including HNSCC by aiding tumor invasion,
immune suppression, and satisfying the metabolic requirements of
rapidly growing tumors (82, 83). This meta-analysis reveals that in
HNSCC, the presence of CAFs is associated with poor
clinicopathologic features. Samples with high CAF density also
demonstrate increased rates of local recurrence (Figure 10).
Understanding the precise mechanisms, and functional
relationship of CAFs with tumor cells will be crucial for
optimizing HNSCC treatment. To this end, the functional and
structural differences between CAF subtypes and normal ﬁbroblasts
need to be more clearly elucidated. The ﬁndings support the
growing interest in CAFs and their potential to be utilized for
clinical stratiﬁcation and decision-making.
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